Nondestructive Quantitative Inspection of Drug Products Using Benchtop NMR Relaxometry—the Case of NovoMix® 30

Batch-level inference-based quality control is the standard practice for drug products. However, rare drug product defects may be missed by batch-level statistical sampling, where a subset of vials in a batch is tested quantitatively but destructively. In 2013, a suspension insulin product, NovoLog® Mix 70/30 was recalled due to a manufacturing error, which resulted in insulin strength deviations up to 50% from the labeled value. This study analyzed currently marketed FlexPen® devices by the water proton transverse relaxation rate using a benchtop nuclear magnetic resonance relaxometer. The water proton transverse relaxation rate was found to be sensitive to detecting concentration changes of the FlexPen® product. These findings support the development of vial-level verification-based quality control for drug products where every vial in a batch is inspected quantitatively but nondestructively.

[1]  W. Straus,et al.  Turning up the heat: Effect of new vaccine for children's (VFC) program recommendations for use of temperature monitors upon incorrect product storage adverse event reporting. , 2018, Vaccine.

[2]  Hydrodynamics of suspensions , 1969 .

[3]  C. Salem,et al.  Drug-Induced Hypoglycaemia , 2011, Drug safety.

[4]  Hanns-Christian Mahler,et al.  A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products , 2016, PDA Journal of Pharmaceutical Science and Technology.

[5]  Insulin therapy and hypoglycemia. , 2012, Endocrinology and metabolism clinics of North America.

[6]  S. Meiboom,et al.  Modified Spin‐Echo Method for Measuring Nuclear Relaxation Times , 1958 .

[7]  M. Taraban,et al.  Water proton NMR detection of amide hydrolysis and diglycine dimerization. , 2018, Chemical communications.

[8]  A. Mantel‐Teeuwisse,et al.  Characteristics of product recalls of biopharmaceuticals and small-molecule drugs in the USA. , 2016, Drug discovery today.

[9]  Harlan M. Krumholz,et al.  Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010 , 2017, JAMA.

[10]  Daniela Verthelyi,et al.  Managing uncertainty: a perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins. , 2012, Journal of pharmaceutical sciences.

[11]  Lawrence X. Yu,et al.  The future of pharmaceutical quality and the path to get there. , 2017, International journal of pharmaceutics.

[12]  K. Nagapudi,et al.  Application of 19 F time‐domain NMR to measure content in fluorine‐containing drug products , 2016, Magnetic resonance in chemistry : MRC.

[13]  Yang Wang,et al.  Design-for-Six-Sigma for Development of a Bioprocess Quality-by-Design Framework , 2011, PDA Journal of Pharmaceutical Science and Technology.

[14]  Douglas P Nesta,et al.  Syringe Filling of High-Concentration mAb Formulation: Slow Suck-Back Pump Speed Prevented Filling Needle Clogging. , 2017, Journal of pharmaceutical sciences.

[15]  C. L. Ventola,et al.  The drug shortage crisis in the United States: causes, impact, and management strategies. , 2011, P & T : a peer-reviewed journal for formulary management.

[16]  H. Butt Controlling the Flow of Suspensions , 2011, Science.